Clinical trials: Solid Tumor, completed
Metastases to Brain
Comparative Evaluation of Two Different Radiosurgery
Randomized double arm phase III study to evaluate feasibility and safety of Gamma Knife radiosurgery and Linac Based (Edge) radiosurgery in brain metastatic patients
- Trial name
- NCT02355613
- Testing
- Radiosurgery with Gamma Knife Perfexion, Linac-based Radiosurgery with EDGE
- Where
- Italy
- Volunteers
- 250 people
- Sponsor
- Istituto Clinico Humanitas
Advanced Solid Tumors
A Phase 1 Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Solid Tumors
This is a multicenter, open-label, dose-exploration and dose-expansion study to evaluate the safety, tolerability, antitumor activity, PK and immunogenicity of MEDI4736 in combination with tremelimumab in subjects with select…
- Trial name
- NCT02261220
- Testing
- MEDI4736, tremelimumab
- Where
- 75 sites in United States, Canada and 7 more
- Volunteers
- 380 people
- Sponsor
- MedImmune LLC
Unspecified Adult Solid Tumor, Protocol Specific
Combination Chemotherapy in Treating Patients With Advanced Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00024323
- Testing
- cisplatin, triapine
- Where
- 2 sites in United States
- Sponsor
- Vion Pharmaceuticals
Refractory Solid Tumors
Phase 1, Multiple Dose Study of MPC-6827 in Subjects With Refractory Solid Tumors
Phase 1, Multiple Dose Study of MPC-6827 in Subjects with Refractory Solid Tumors.
- Trial name
- NCT00394446
- Testing
- MPC-6827
- Where
- 2 sites in United States
- Volunteers
- 48 people
- Sponsor
- Myrexis Inc.
Advanced Cancer
Latent Tuberculosis Infection in Cancer Patients
Primary Objective: 1. To evaluate the performance of the new T-SPOT.TB test and the conventional TST for screening of Latent Tuberculosis infections in patients with cancer and those undergoing Hematopoietic Stem Cell Transplant.
- Trial name
- NCT00507754
- Testing
- T-SPOT TB test
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced Solid Tumors
A Study of Dose Escalation of IBI321 in Patients With Advanced Solid Tumors
This first-in-human open-label, multicenter, dose-escalation and expansion study is designed to evaluate the safety, tolerability, and primary efficacy of IBI321 in participants with locally advanced, recurrent, or metastatic…
- Trial name
- NCT04911894
- Testing
- IBI321
- Where
- China
- Volunteers
- 16 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Locally Advanced/Metastatic Solid Tumors
HY-0102 Monotherapy in Patients With Locally Advanced/Metastatic Solid Tumours
This is a Phase I, first-in-human trial to evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of HY-0102 administered intravenously (IV) once every two weeks in adult patients with locally…
- Trial name
- NCT04914351
- Testing
- HY-0102
- Where
- 3 sites in United States
- Volunteers
- 17 people
- Sponsor
- Shanghai HyaMab Biotech Co.,Ltd.
Advanced Solid Tumor
Phase 1 Study of IM156 in Patients With Advanced Solid Tumor and Lymphoma
The main purpose of first-in-human IM156 study is to evaluate the safety and tolerability, and to determine the maximum tolerated dose and recommended phase 2 dose of IM156.
- Trial name
- NCT03272256
- Testing
- IM156
- Where
- 3 sites in South Korea
- Volunteers
- 22 people
- Sponsor
- ImmunoMet Therapeutics, Inc.
Neoplasms
Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer
Determine the safety, tolerability, and maximum tolerated dose (MTD) of IV administered VIP236 as monotherapy in patients with advanced solid tumor cancer
- Trial name
- NCT05712889
- Testing
- VIP236 (Q3W), VIP236 (Q2W)
- Where
- 6 sites in United States, Australia
- Volunteers
- 29 people
- Sponsor
- Vincerx Pharma, Inc.
Solid Tumors
A Dose Escalation Study of OMP-59R5 in Subjects With Solid Tumors
This is an open-label Phase 1 dose escalation study of OMP-59R5 in subjects with previously treated solid tumors for which there is no remaining standard curative therapy and no therapy with a demonstrated survival benefit.
- Trial name
- NCT01277146
- Testing
- OMP-59R5
- Where
- 2 sites in United States
- Volunteers
- 42 people
- Sponsor
- OncoMed Pharmaceuticals, Inc.
Solid Tumors
Dose Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous ALN-VSP02 In Patients With Advanced Solid Tumors With Liver Involvement
The purpose of the study is to determine the safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous ALN-VSP02, an RNAi therapeutic, in patients with advanced solid tumors with liver involvement.
- Trial name
- NCT00882180
- Testing
- ALN-VSP02
- Where
- 10 sites in United States, Spain
- Volunteers
- 41 people
- Sponsor
- Alnylam Pharmaceuticals
Advanced Lung Cancer, Ovarian Cancer
Clinical Study of AL2846 Capsules in the Treatment of Advanced Lung Tumor and Advanced Ovarian Cancer
This is a multi-cohort, randomized, open, multicenter Phase II study to evaluate the efficacy and safety of AL2846 capsules in patients with advanced lung cancer and ovarian cancer.
- Trial name
- NCT05815862
- Testing
- AL2846 capsule
- Where
- 4 sites in China
- Volunteers
- 29 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Unspecified Adult Solid Tumor, Protocol Specific
GPX-100 in Treating Patients With Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of GPX-100 in treating patients who have solid tumors.
- Trial name
- NCT00003403
- Testing
- GPX-100
- Where
- 2 sites in United States
- Sponsor
- Gem Pharmaceuticals
Neoplasms
Safety Study of rhuMAb 2C4 to Treat Advanced Solid Tumors
The purpose of this Phase I study is to test the safety of rhuMAb 2C4 to see what effects (good and bad) it has on patients with certain types of cancer, and also to find the highest dose of rhuMAb that can be given without…
- Trial name
- NCT00027027
- Testing
- rhuMAb 2C4
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Genentech, Inc.
Advanced Solid Tumors
A Phase I Study of MSB2311 in Advanced Solid Tumors
This is a phase I study to determine the safety and toxicity, PK/PD, immunogenicity, biomarkers, anti-tumor activity and establish a preliminary recommended Phase 2 dose (RP2D) in subjects with advanced solid tumors.
- Trial name
- NCT03463473
- Testing
- 3 mg/kg Q3W MSB2311 Injection, 10 mg/kg Q3W MSB2311 Injection, 20 mg/kg Q3W MSB2311 Injection
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Transcenta Therapeutics (Hangzhou) Co., Ltd.
Malignant Neoplasm
A Safety and Pharmacokinetic Study of NBM-BMX Administered Orally to Patients With Advanced Cancer
NBM-BMX is a new small molecule chemical entity being developed as a potential anti-cancer therapeutic by NatureWise. NBM-BMX is a histone deacetylase (HDAC) inhibitor and has been shown to be particularly active against HDAC8.
- Trial name
- NCT03726294
- Testing
- NBM-BMX softgel capsules
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- NatureWise Biotech & Medicals Corporation
Advanced Solid Tumor
A Study of hSTC810 With Advanced/Metastatic Solid Tumors (STCUBE-001)
The Purpose of this study is to investigate the safety, tolerability, pharmacokinetics, and preliminary efficacy of hSTC810 monotherapy in participants with advanced solid tumors.
- Trial name
- NCT05231746
- Testing
- hSTC810
- Where
- 5 sites in United States, South Korea
- Volunteers
- 47 people
- Sponsor
- STCube, Inc.
Advanced Solid Tumors
Phase I Study of Indibulin in Combination With Erlotinib in Advanced Solid Tumors
Single arm, open label, Phase I, dose-escalation study of indibulin in combination with erlotinib in subjects with advanced histologically confirmed, solid tumors for which no standard therapy exists and for whom treatment with…
- Trial name
- NCT00591383
- Testing
- indibulin, erlotinib
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Alaunos Therapeutics
Advanced Solid Tumors
A Study of Niraparib as Single Agent in Participants With Advanced Solid Tumors
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of Niraparib in Japanese participants with advanced solid tumors.
- Trial name
- NCT03497429
- Testing
- Niraparib
- Where
- Japan
- Volunteers
- 9 people
- Sponsor
- Takeda
Solid Tumors
Anti-EGFR Immunoliposomes in Solid Tumors
Background: Site-specific delivery of anti-cancer therapeutics is paramount for both reducing nonspecific toxicities and increasing efficacy of chemotherapeutic agents.
- Trial name
- NCT01702129
- Testing
- anti-EGFR immunoliposomes loaded with doxorubicin
- Where
- Switzerland
- Volunteers
- 26 people
- Sponsor
- University Hospital, Basel, Switzerland
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.